A Remarkable Result from Treatment for Invasive Lobular Breast Cancer with ECCT and Hormonal Therapy

Madam Tan, 58 years old, Malaysia, In early 2025, she was diagnosed with invasive lobular breast cancer, hormone receptor positive (ER/PR+) and HER2 negative (Stage 4 Breast Cancer with Bone Metastases). Imaging revealed a large tumor in her left breast, with possible invasion into the pectoral muscle, along with extensive bone metastases throughout her spine and pelvis. At the time, she experienced severe back pain, fatigue, and unintended weight loss — all signs of advanced-stage disease.

Rather than undergoing immediate chemotherapy, she chose an integrative treatment approach as Treatment for Invasive Lobular Breast Cancer that combined conventional and non-invasive options:

✅ ECCT — initiated in January 2025 and used consistently for over 5 months

✅ Hormonal therapy (Femara 2.5 mg daily) — started 25 January 2025

✅ Ribociclib (400 mg) — taken alongside Femara and recently stopped due to elevated liver enzyme levels

✅ Bone strengthening (Xgeva) — with the 4th injection administered in mid-June 2025

📈 Encouraging Medical Progress

After five months of treatment, a CT scan in late June 2025 showed clear clinical improvement:

🔹 The breast tumor had shrunk dramatically from about 4 cm down to 1.7 x 1.2 cm

🔹 The previously suspicious enhancement in the pectoral muscle had completely resolved

🔹 No new metastatic sites were found

🔹 The bone metastases, once widespread and lytic, showed early sclerotic changes, suggesting a treatment response

🔹 Lung, liver, and adrenal lesions remained stable

🔹 Blood tests, including a downward trend in ALP, indicated possible reduction in cancer activity

💬 Improved Quality of Life

Her daily condition improved noticeably:

• Back pain became occasional and localized

• Energy, appetite, and sleep returned to normal

• She remained alert, coherent, and active in daily life

• Only mild joint aches, possibly from hormone therapy

This case highlights the potential of a combined approach, using ECCT, hormonal therapy, and supportive care to achieve tumor regression and stabilize metastatic disease, even in Stage 4 breast cancer. The patient’s steady progress over just five months shows how thoughtful, multidisciplinary care can bring hope and tangible improvement while maintaining good quality of life.